PMID- 25648097
OWN - NLM
STAT- MEDLINE
DCOM- 20170118
LR  - 20220408
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Print)
IS  - 1598-2998 (Linking)
VI  - 47
IP  - 4
DP  - 2015 Oct
TI  - Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic 
      Myeloid Leukemia.
PG  - 937-42
LID - 10.4143/crt.2013.155 [doi]
AB  - We describe two cases of pulmonary arterial hypertension (PAH) that occurred 
      under dasatinib treatment and were resolved after dasatinib discontinuation. Two 
      patients with chronic phase chronic myeloid leukemia (CML) were switched to 
      dasatinib therapy because of hematological progress while receiving imatinib. 
      These patients had New York Heart Association (NYHA) functional class II dyspnea 
      with elevated right ventricular systolic pressure (RVSP), which progressed under 
      dasatinib treatment. After dasatinib treatment was discontinued, subjective 
      symptoms were improved to NYHA functional class I and the follow-up transthoracic 
      Doppler echocardiography showed improved RVSP. Treatment with an alternate 
      tyrosine kinase inhibitor was initiated and had been continued without 
      development of dyspnea or elevation of RVSP. This report suggests that dasatinib 
      can cause the reversible PAH, therefore, routine cardiopulmonary evaluation 
      before and during treatment with dasatinib may be needed in CML patients with 
      clinical manifestations.
FAU - Hong, Ji Hyung
AU  - Hong JH
AD  - Division of Oncology, Department of Internal Medicine, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Lee, Sung-Eun
AU  - Lee SE
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
AD  - Division of Hematology, Department of Internal Medicine, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Choi, Soo Young
AU  - Choi SY
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Kim, Soo-Hyun
AU  - Kim SH
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Jang, Eun-Jung
AU  - Jang EJ
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Bang, Ju-Hee
AU  - Bang JH
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Park, Jin Eok
AU  - Park JE
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Jeon, Hye-Rim
AU  - Jeon HR
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Oh, Yun Jeong
AU  - Oh YJ
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Yi, Jeong-Eun
AU  - Yi JE
AD  - Division of Cardiology, Department of Internal Medicine, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Jung, Hae Ok
AU  - Jung HO
AD  - Division of Cardiology, Department of Internal Medicine, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Youn, Ho Joong
AU  - Youn HJ
AD  - Division of Cardiology, Department of Internal Medicine, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Kim, Dong-Wook
AU  - Kim DW
AD  - Cancer Research Institute, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
AD  - Division of Hematology, Department of Internal Medicine, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20141117
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Diuretics)
RN  - 0 (Vasodilator Agents)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - Antineoplastic Agents/*adverse effects/*therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Dasatinib/*adverse effects/*therapeutic use
MH  - Diuretics/therapeutic use
MH  - Humans
MH  - Hypertension, Pulmonary/*chemically induced/therapy
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Sildenafil Citrate/therapeutic use
MH  - Vasodilator Agents/therapeutic use
PMC - PMC4614213
OTO - NOTNLM
OT  - Chronic myeloid leukemia
OT  - Dasatinib
OT  - Pulmonary arterial hypertension
COIS- Conflict of interest relevant to this article was not reported.
EDAT- 2015/02/05 06:00
MHDA- 2017/01/19 06:00
PMCR- 2015/10/01
CRDT- 2015/02/05 06:00
PHST- 2013/08/23 00:00 [received]
PHST- 2014/02/24 00:00 [accepted]
PHST- 2015/02/05 06:00 [entrez]
PHST- 2015/02/05 06:00 [pubmed]
PHST- 2017/01/19 06:00 [medline]
PHST- 2015/10/01 00:00 [pmc-release]
AID - crt.2013.155 [pii]
AID - crt-2013-155 [pii]
AID - 10.4143/crt.2013.155 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2015 Oct;47(4):937-42. doi: 10.4143/crt.2013.155. Epub 2014 Nov 
      17.